{"id":8364,"date":"2025-11-24T18:02:13","date_gmt":"2025-11-24T18:02:13","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8364"},"modified":"2025-11-24T18:02:13","modified_gmt":"2025-11-24T18:02:13","slug":"a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/","title":{"rendered":"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Sustained pain reduction, improved mobility, and strong safety profile position Allocetra\u2122 as a potential game-changer for aging patients<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Enlivex Therapeutics Ltd., a Nasdaq-listed clinical-stage immunotherapy company, has announced compelling six-month efficacy results from the Phase IIa portion of its multinational Phase I\/II Allocetra\u2122 trial for moderate to severe knee osteoarthritis (OA). The latest findings reinforce earlier three-month data and highlight a clear responder population among adults aged 60 and older, suggesting a meaningful therapeutic breakthrough in a field long dominated by pain management rather than disease-modifying solutions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study demonstrated that Allocetra\u2122\u2014a macrophage reprogramming treatment designed to modulate inflammation\u2014produced substantial and durable reductions in pain while improving physical function. In patients aged 60+, the therapy showed a statistically significant improvement at three months, with a 99% greater reduction in composite pain and function scores compared to placebo. At six months, this benefit persisted, with an 80% improvement over placebo in patients aged 61 and older. These results underscore not only efficacy, but durability\u2014an especially notable outcome given that a single treatment cycle generated at least half a year of sustained clinical benefit.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Equally important, Allocetra\u2122 maintained a favorable safety profile throughout the six-month follow-up, mirroring earlier findings and reinforcing its potential as a viable long-term therapy. As knee osteoarthritis continues to rise due to aging and obesity, experts view innovative immune-modulating strategies as essential. Professor Philip Conaghan, an international leader in OA research, praised the study\u2019s promise, emphasizing the growing need for effective treatments that target inflammatory pathways.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Enlivex leadership echoed this optimism. CEO Dr. Oren Hershkovitz highlighted both the therapeutic impact and commercial potential, while CMO Dr. Einat Galamidi confirmed plans to launch a Phase IIb trial in early 2026. If future results continue this trajectory, Allocetra\u2122 could represent a transformative new option for millions suffering from age-related knee osteoarthritis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/powering-the-next-era-of-public-sector-ai-amazons-historic-50-billion-aws-investment\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Powering the Next Era of Public Sector AI: Amazon\u2019s Historic $50 Billion AWS Investment<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sustained pain reduction, improved mobility, and strong safety profile position Allocetra\u2122 as a potential game-changer for aging patients Enlivex Therapeutics Ltd., a Nasdaq-listed clinical-stage immunotherapy company, has announced compelling six-month efficacy results from the Phase IIa portion of its multinational Phase I\/II Allocetra\u2122 trial for moderate to severe knee osteoarthritis (OA). The latest findings reinforce [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1424,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,359],"tags":[858,421,416,418,417],"coauthors":[454],"class_list":["post-8364","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-small-cap","tag-enlv","tag-growth","tag-movers","tag-news","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Sustained pain reduction, improved mobility, and strong safety profile position Allocetra\u2122 as a potential game-changer for aging patients Enlivex Therapeutics Ltd., a Nasdaq-listed clinical-stage immunotherapy company, has announced compelling six-month efficacy results from the Phase IIa portion of its multinational Phase I\/II Allocetra\u2122 trial for moderate to severe knee osteoarthritis (OA). The latest findings reinforce [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T18:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mart-production-7088530-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra\",\"datePublished\":\"2025-11-24T18:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/\"},\"wordCount\":331,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mart-production-7088530-scaled.jpg\",\"keywords\":[\"ENLV\",\"Growth\",\"Movers\",\"News\",\"Stock Market\"],\"articleSection\":[\"Biotechnology\",\"Small-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/\",\"name\":\"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mart-production-7088530-scaled.jpg\",\"datePublished\":\"2025-11-24T18:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mart-production-7088530-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-mart-production-7088530-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"radiology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/11\\\/24\\\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/","og_locale":"en_US","og_type":"article","og_title":"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra - Stoxpo","og_description":"Sustained pain reduction, improved mobility, and strong safety profile position Allocetra\u2122 as a potential game-changer for aging patients Enlivex Therapeutics Ltd., a Nasdaq-listed clinical-stage immunotherapy company, has announced compelling six-month efficacy results from the Phase IIa portion of its multinational Phase I\/II Allocetra\u2122 trial for moderate to severe knee osteoarthritis (OA). The latest findings reinforce [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/","og_site_name":"Stoxpo","article_published_time":"2025-11-24T18:02:13+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mart-production-7088530-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra","datePublished":"2025-11-24T18:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/"},"wordCount":331,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mart-production-7088530-scaled.jpg","keywords":["ENLV","Growth","Movers","News","Stock Market"],"articleSection":["Biotechnology","Small-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/","url":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/","name":"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mart-production-7088530-scaled.jpg","datePublished":"2025-11-24T18:02:13+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mart-production-7088530-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-mart-production-7088530-scaled.jpg","width":2560,"height":1707,"caption":"radiology"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2025\/11\/24\/a-breakthrough-in-knee-osteoarthritis-enlivex-reports-promising-six-month-results-for-allocetra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8364"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8364\/revisions"}],"predecessor-version":[{"id":8365,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8364\/revisions\/8365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1424"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8364"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}